{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Carcinoma&page=13", "query": { "condition": "Gastrointestinal Carcinoma", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 2726, "total_pages": 273, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Carcinoma&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Gastrointestinal+Carcinoma&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T22:37:24.595Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06872515", "title": "Impact of Prehabilitation in Oncology Via Exercise- Esophageal (IMPROVE-Esophageal)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Esophageal Cancer", "Esophageal Carcinoma" ], "interventions": [ { "name": "Exercise and Nutrition", "type": "BEHAVIORAL" }, { "name": "Usual Care Group", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2025-07-16", "completion_date": "2027-10-01", "has_results": false, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-10-13T22:37:24.595Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06872515" }, { "nct_id": "NCT05733611", "title": "RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Refractory Metastatic Colorectal Cancer", "pMMR", "MSS" ], "interventions": [ { "name": "RP2", "type": "BIOLOGICAL" }, { "name": "RP3", "type": "BIOLOGICAL" }, { "name": "atezolizumab", "type": "BIOLOGICAL" }, { "name": "bevacizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Replimune, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2023-06-29", "completion_date": "2025-08-18", "has_results": false, "last_update_posted_date": "2026-02-02", "last_synced_at": "2026-10-13T22:37:24.595Z", "location_count": 2, "location_summary": "Los Angeles, California • Seattle, Washington", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05733611" }, { "nct_id": "NCT01140347", "title": "A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "Ramucirumab DP (IMC-1121B)", "type": "BIOLOGICAL" }, { "name": "BSC", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 565, "start_date": "2010-10", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2015-12-28", "last_synced_at": "2026-10-13T22:37:24.595Z", "location_count": 18, "location_summary": "Orange, California • San Francisco, California • New Haven, Connecticut + 15 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01140347" }, { "nct_id": "NCT01387932", "title": "HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "HepaSphere/QuadraSphere Microspheres", "type": "DEVICE" }, { "name": "PVA, lipiodol, doxorubicin", "type": "PROCEDURE" } ], "intervention_types": [ "DEVICE", "PROCEDURE" ], "sponsor": "Merit Medical Systems, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 235, "start_date": "2011-06", "completion_date": "2021-02", "has_results": true, "last_update_posted_date": "2021-11-30", "last_synced_at": "2026-10-13T22:37:24.595Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01387932" }, { "nct_id": "NCT03801915", "title": "Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colon Cancer", "Pancreatic Cancer", "Cholangiocarcinoma", "Metastatic Colon Carcinoma", "Liver Metastasis" ], "interventions": [ { "name": "MVT-5873", "type": "DRUG" }, { "name": "pancreatectomy or hepatectomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2019-11-13", "completion_date": "2022-05-27", "has_results": true, "last_update_posted_date": "2023-03-21", "last_synced_at": "2026-10-13T22:37:24.595Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03801915" }, { "nct_id": "NCT00712855", "title": "A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "mapatumumab", "type": "BIOLOGICAL" }, { "name": "sorafenib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Human Genome Sciences Inc., a GSK Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2008-06", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2012-10-30", "last_synced_at": "2026-10-13T22:37:24.595Z", "location_count": 6, "location_summary": "Los Angeles, California • Aurora, Colorado • Gainesville, Florida + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00712855" }, { "nct_id": "NCT01191385", "title": "GIDEON Non-Nexavar Arm - HCC Patients Who Are Treated With Any Therapy Other Than Nexavar at Individual Study Start", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Carcinoma, Hepatocellular" ], "interventions": [ { "name": "Any treatment for unresectable HCC as chosen by the physician", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2010-11", "completion_date": "2013-12", "has_results": false, "last_update_posted_date": "2017-08-16", "last_synced_at": "2026-10-13T22:37:24.595Z", "location_count": 24, "location_summary": "Multiple Locations, Arkansas • Multiple Locations, California • Multiple Locations, Colorado + 21 more", "locations": [ { "city": "Multiple Locations", "state": "Arkansas" }, { "city": "Multiple Locations", "state": "California" }, { "city": "Multiple Locations", "state": "Colorado" }, { "city": "Multiple Locations", "state": "District of Columbia" }, { "city": "Multiple Locations", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01191385" }, { "nct_id": "NCT05111314", "title": "Comparison of Hepatic Intraarterial Versus Systemic Intravenous 68Ga-PSMA PET/CT for Detection of Hepatocellular Carcinoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Gallium Ga 68 Gozetotide", "type": "RADIATION" }, { "name": "Hepatic Artery Embolization", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography and Computed Tomography Scan", "type": "PROCEDURE" } ], "intervention_types": [ "RADIATION", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2022-02-11", "completion_date": "2023-08-14", "has_results": false, "last_update_posted_date": "2023-11-07", "last_synced_at": "2026-10-13T22:37:24.595Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05111314" }, { "nct_id": "NCT04607291", "title": "Health Service Intervention for the Improvement of Access and Adherence to Colorectal Cancer Screening", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Carcinoma" ], "interventions": [ { "name": "Community Health Service", "type": "OTHER" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "50 Years to 75 Years" }, "enrollment_count": 183, "start_date": "2019-09-01", "completion_date": "2021-05-14", "has_results": true, "last_update_posted_date": "2021-08-12", "last_synced_at": "2026-10-13T22:37:24.595Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04607291" }, { "nct_id": "NCT05822752", "title": "Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Budigalimab", "type": "DRUG" }, { "name": "Livmoniplimab", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2023-09-21", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2025-08-14", "last_synced_at": "2026-10-13T22:37:24.595Z", "location_count": 20, "location_summary": "Prescott Valley, Arizona • Springdale, Arkansas • Los Angeles, California + 15 more", "locations": [ { "city": "Prescott Valley", "state": "Arizona" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05822752" } ] }